Ryan C. Widau - Concepedia

Author

Ryan C. Widau

Eli Lilly (United States)

Also Known As

R Widau, R. Widau, R.C. Widau, Ryan C Widau, Ryan C. Widau, Ryan Cole Widau, Ryan Widau

Publications

1.2K

Citations

H-Index

Concepts

All Affiliations

Eli Lilly (United States)University of California, Los Angeles Massachusetts General Hospital Johannes Gutenberg University Mainz Icahn School of Medicine at Mount Sinai

About

Ryan C. Widau is an author at Eli Lilly (United States) specializing in medicine, oncology, and health sciences.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	471
2	Health Sciences	3	3	296
3	Immunology	2	2	25
4	Cell Biology	1	1	14
5	Hepatology	1	1	11

Ryan C. Widau

Publications

1.1K

Citations

H-Index

Page 1

	Year	Citations
Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial Roy S. Herbst, Hendrik‐Tobias Arkenau, Rafael Santana-Dávila, The Lancet Oncology Urothelial CarcinomasMedicineClinical TrialsPathologyImmune Checkpoint Inhibitor	2019	271
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial Daniel P. Petrylak, Ronald de Wit, Kim N., The Lancet Platinum-based TherapyUrologyMetastatic Urothelial CarcinomaGenitourinary CancerMedicine	2017	175
Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open-Label, Phase I Trial (JVDF) Hendrik‐Tobias Arkenau, Juan Martín-Liberal, Emiliano Calvo, The Oncologist	2018	166
STING Promotes Homeostasis via Regulation of Cell Proliferation and Chromosomal Stability Diana Rose E. Rañoa, Ryan C. Widau, Stephen Mallon, Cancer Research	2018	95
RIG-I–like receptor LGP2 protects tumor cells from ionizing radiation Ryan C. Widau, Akash D. Parekh, M.C. Ranck, Proceedings of the National Academy of Sciences	2014	88
Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab Andrew X. Zhu, Richard S. Finn, Yoon‐Koo Kang, British Journal of Cancer	2021	63
Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2 Masatoshi Kudo, Peter R. Galle, Giovanni Brandi, JHEP Reports	2020	53
Protein Phosphatase 2A (PP2A) Holoenzymes Regulate Death-associated Protein Kinase (DAPK) in Ceramide-induced Anoikis Ryan C. Widau, Yijun Jin, Shelley A.H. Dixon, Journal of Biological Chemistry	2010	51
Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha‐fetoprotein after sorafenib in REACH and REACH‐2 Masatoshi Kudo, Peter R. Galle, Josep M. Llovet, Liver International	2020	31
Pattern of progression in advanced hepatocellular carcinoma treated with ramucirumab María Reig, Peter R. Galle, Masatoshi Kudo, Liver International	2020	22

Page 1